Zurcher Kantonalbank Zurich Cantonalbank Invests $73,000 in Tempus AI, Inc. (NASDAQ:TEM)

Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Tempus AI, Inc. (NASDAQ:TEM) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,511 shares of the company’s stock, valued at approximately $73,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Operose Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $25,000. Cherry Tree Wealth Management LLC bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $31,000. Continuum Advisory LLC bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $39,000. Bartlett & CO. Wealth Management LLC raised its holdings in shares of Tempus AI by 100.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock worth $39,000 after purchasing an additional 400 shares during the period. Finally, Signaturefd LLC bought a new stake in shares of Tempus AI in the 1st quarter worth approximately $48,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, EVP Erik Phelps sold 51,317 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $72.56, for a total transaction of $3,723,561.52. Following the completion of the transaction, the executive vice president owned 97,779 shares of the company’s stock, valued at approximately $7,094,844.24. This trade represents a 34.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $70.07, for a total transaction of $17,517,500.00. Following the sale, the chief executive officer owned 9,357,283 shares in the company, valued at approximately $655,664,819.81. The trade was a 2.60% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 758,772 shares of company stock valued at $51,005,175. 27.60% of the stock is currently owned by company insiders.

Tempus AI Price Performance

TEM stock opened at $60.87 on Monday. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $91.45. The company has a market cap of $10.54 billion, a P/E ratio of -51.15 and a beta of 4.98. The firm has a 50-day moving average of $62.47 and a 200 day moving average of $58.08. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.71 and a quick ratio of 1.56.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 157.53%. The company had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. During the same period in the prior year, the firm earned ($6.86) earnings per share. Tempus AI’s revenue was up 89.5% on a year-over-year basis. On average, sell-side analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. BTIG Research assumed coverage on shares of Tempus AI in a report on Friday. They set a “buy” rating and a $60.00 target price on the stock. Guggenheim upped their price target on shares of Tempus AI from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, June 30th. Bank of America increased their price objective on Tempus AI from $68.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 25th. Morgan Stanley lifted their price objective on Tempus AI from $60.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $70.00 target price on shares of Tempus AI in a research report on Friday. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $65.09.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.